Efaproxiral clinical trials
How each study uses efaproxiral is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2000 (2)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2002 | 1 |
| 2004 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Spectrum Pharmaceuticals, Inc (3) · New Approaches to Brain Tumor Therapy Consortium (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses efaproxiral is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Radiation Therapy With or Without RSR13 in Treating Patients With Brain MetastasesCompletedPhase 3Spectrum Pharmaceuticals, IncNCT00005887Written as efaproxiral
- Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant GliomaCompletedPhase 1/2New Approaches to Brain Tumor Therapy ConsortiumNCT00005855Written as efaproxiral
- Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast CancerCompletedPhase 3Spectrum Pharmaceuticals, IncNCT00083304Written as Efaproxiral
- Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung CancerWithdrawnPhase 3Spectrum Pharmaceuticals, IncNCT00055887Written as efaproxiral
Codes
What other systems call efaproxiral · ClinicalTrials.gg INT003551
- MeSH (NLM) C067396efaproxiralConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) J81E81G364EFAPROXIRALConfirmed FDA, NLM, Wikidata
- RxNorm 40365One source Wikidata
- Wikidata Q5347186efaproxiralConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1435EfaproxiralOne source FDA
- DrugBank DB08486One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C067396 | efaproxiral | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | J81E81G364 | EFAPROXIRAL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 40365 | — | One source Wikidata |
| Wikidata | Q5347186 | efaproxiral | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1435 | Efaproxiral | One source FDA |
| DrugBank | DB08486 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.